title: Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer.
abstract: Screening for prostate cancer using prostate-specific antigen (PSA) tests has led to a stage and grade shift as compared to the pre-PSA era. Effectiveness of screening for prostate cancer should be manifested by a reduction in detection rate of aggressive cancers during subsequent screening. In 6 centers of the European Randomized Screening study for Prostate Cancer, a total of 58,710 men were tested for prostate cancer. Screening centers differed with regard to age-range, screening interval and biopsy indications. During the 2nd visit, the proportion of Gleason score 6 cancers increased from 62.5 to 75%, mainly at the expense of Gleason score 7 cancers. High-grade (Gleason score 8-10) cancer detection rates varied per screening center during the 1st visit from 5.1 to 41.1, and during the 2nd visit from 6.4 to 29.3/10,000 men. The overall detection rate of high-grade cancers showed a reduction during the 2nd visit from 26 to 12/10,000 men, an effect mainly attributable to the screening center with the highest cancer detection rate (i.e. 507/10,000 men). Variations in detection rates among screening centers related among others to biopsy compliance and age range.
authors.affiliation: Department of Pathology and Urology, Erasmus Medical Center, Rotterdam, the Netherlands, and Centro per la Studio e la Prevenzione Oncologica, University of Florence, Italy. tvanderkwast@mtsinai.on.ca
authors.forename: Theodorus H
authors.initials: TH
authors.lastname: van der Kwast
authors.forename: Stefano
authors.initials: S
authors.lastname: Ciatto
authors.forename: Paula M
authors.initials: PM
authors.lastname: Martikainen
authors.forename: Robert
authors.initials: R
authors.lastname: Hoedemaeker
authors.forename: Marita
authors.initials: M
authors.lastname: Laurila
authors.forename: Carl-Gustaph
authors.initials: CG
authors.lastname: Pihl
authors.forename: Jonas
authors.initials: J
authors.lastname: Hugosson
authors.forename: Ingrid
authors.initials: I
authors.lastname: Neetens
authors.forename: Vera
authors.initials: V
authors.lastname: Nelen
authors.forename: Simonetta
authors.initials: S
authors.lastname: Di Lollo
authors.forename: Monique J
authors.initials: MJ
authors.lastname: Roobol
authors.forename: Liisa
authors.initials: L
authors.lastname: Määtänen
authors.forename: Carlos
authors.initials: C
authors.lastname: Santonja
authors.forename: Sue
authors.initials: S
authors.lastname: Moss
authors.forename: Fritz H
authors.initials: FH
authors.lastname: Schröder
mesh_terms: D000367:Age Factors; D000368:Aged; D001706:Biopsy; D006801:Humans; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D009367:Neoplasm Staging; D010349:Patient Compliance; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D015203:Reproducibility of Results
chemical_list: D017430:Prostate-Specific Antigen